Related Experiment Video
Updated: Jan 21, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Long-term outcome and unmet needs in infantile-onset Pompe disease
1Department of Child Neurology, Justus-Liebig-University, Giessen, Germany.
Insights
Infantile-onset Pompe disease (IOPD) is a severe condition. Enzyme replacement therapy (ERT) has improved outcomes but does not fully address the complex multisystemic nature of IOPD.
Area of Science:
- Biochemistry
- Genetics
- Pediatric Medicine
Background:
- Infantile-onset Pompe disease (IOPD) is a rare genetic disorder caused by deficient acid alpha-glucosidase (GAA) activity.
- This deficiency leads to severe hypertrophic cardiomyopathy (HCM) and skeletal muscle weakness, often resulting in early mortality.
Purpose of the Study:
- To review the complex multisystemic phenotype of IOPD that has emerged with enzyme replacement therapy (ERT).
- To outline current challenges and unmet needs associated with ERT for IOPD.
Main Methods:
- Literature review of studies on IOPD and ERT.
- Analysis of clinical outcomes and long-term effects of ERT.
Main Results:
- ERT has improved HCM, motor function, and survival in IOPD patients since its approval in 2006.
- ERT has revealed a more complex, multisystemic disease presentation than previously recognized.
- Despite ERT, significant mortality and progressive motor decline persist in long-term survivors.
Conclusions:
- ERT has transformed IOPD prognosis but has not eliminated mortality or functional decline.
- A deeper understanding of the IOPD phenotype and ERT-related issues is crucial.
- Addressing unmet needs is essential for improving long-term management of IOPD.
Abstract:
Infantile-onset Pompe disease (IOPD) is characterized by virtually complete absence of acid alpha-glucosidase (GAA)-activity, resulting in rapidly progressive hypertrophic cardiomyopathy (HCM), profound skeletal muscle weakness, and death usually within the first 12 months of life. Enzyme replacement therapy (ERT) with recombinant GAA in humans started in 1999, and pivotal studies demonstrated that the treatment ameliorated HCM, improved motor function in some patients, and prolonged overall and ventilator-free survival. These outcomes led to the approval of ERT in 2006. Implementation of ERT has uncovered multisystemic character of IOPD, not known in the pre-ERT era. Although ERT has substantially improved the prognosis of IOPD, mortality is still considerable, and decline of motor function with time is frequent in long-term survivors. This review details the new complex IOPD phenotype, outlines problems related to ERT, and highlights unmet needs.
More Related Videos
05:34A Mouse Model to Evaluate the Long-Term Structural and Functional Outcomes after the Reversal of Prolonged Unilateral Ureteric Obstruction
Published on: July 18, 2025
09:59A Magnetic Resonance Imaging Protocol for Stroke Onset Time Estimation in Permanent Cerebral Ischemia
Published on: September 16, 2017
Related Concept Videos
Predicting Reaction Outcomes
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
Long-term Depression
Long-term Depression
Calcium Ion Concentration Mechanism
If over...
Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
Directional Terms